The investment of ₹1,100 crore for the project will be raised from internal accruals and works are expected to be completed ...

Revenue from operations grew 10.5% yoy to ₹13,675.4 crore, compared with ₹12,381 crore registered for the same period in Q3 ...

Net Interest Income was up by 12% to ₹2,830 crore YoY, having stood at ₹2,525 crore in Q3 FY24, reporting strong core ...

EBITDA declined 4.8% YoY to ₹3,069.4 crore, though EBITDA margin rose by 50 basis points to 13.4% from 12.9% last year.

Dr Lal Pathlabs Ltd EBITDA grew 9.5% YoY to ₹154 crore, though margins contracted slightly to 25.8% from 26.1% last year ...

EBITDA rose 30.4% YoY to ₹109.3 crore, as against ₹83.8 crore in the previous year, led by operational efficiencies and robust order execution. EBITDA margin expanded to 21.7%, up from 19.4% in Q3 ...

The company’s revenue for the quarter registered an increase of 116% y-o-y to ₹3,457 Crore as compared to ₹1,596 Crore.

The industry hopes for more headroom for higher allocations for rural development schemes to pump up sales in smaller towns ...

Pfizer India posts ₹127.6 crore net profit in Q3 FY25; that’s 1.9% of ₹130 crore in the same period last year. Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 ...

The company registered a 28% increase in its December quarter’s Asset Under Management (AUM) at ₹3,98,043 Crore.

The board approved the second interim dividend of ₹5 per share amounting to 100% of face value, amounting to ₹6,290 crore.

The currency has been under pressure, thus stabilizing it involves injecting Rs 600 billion into banks through bond purchases ...